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Experimental methods are commonly used for patient-specific IMRT delivery 
verification. There are a variety of IMRT QA techniques which have been proposed 
and clinically used with a common understanding that not one single method can 
detect all possible errors. The aim of this work was to compare the efficiency and 
effectiveness of independent dose calculation followed by machine log file analysis 
to conventional measurement-based methods in detecting errors in IMRT delivery. 
Sixteen IMRT treatment plans (5 head-and-neck, 3 rectum, 3 breast, and 5 prostate 
plans) created with a commercial treatment planning system (TPS) were recalculated 
on a QA phantom. All treatment plans underwent ion chamber (IC) and 2D diode 
array measurements. The same set of plans was also recomputed with another com-
mercial treatment planning system and the two sets of calculations were compared. 
The deviations between dosimetric measurements and independent dose calculation 
were evaluated. The comparisons included evaluations of DVHs and point doses 
calculated by the two TPS systems. Machine log files were captured during pre-
treatment composite point dose measurements and analyzed to verify data transfer 
and performance of the delivery machine. Average deviation between IC measure-
ments and point dose calculations with the two TPSs for head-and-neck plans were 
1.2 ± 1.3% and 1.4 ± 1.6%, respectively. For 2D diode array measurements, the 
mean gamma value with 3% dose difference and 3 mm distance-to-agreement was 
within 1.5% for 13 of 16 plans. The mean 3D dose differences calculated from two 
TPSs were within 3% for head-and-neck cases and within 2% for other plans. The 
machine log file analysis showed that the gantry angle, jaw position, collimator 
angle, and MUs were consistent as planned, and maximal MLC position error was 
less than 0.5 mm. The independent dose calculation followed by the machine log 
analysis takes an average 47 ± 6 minutes, while the experimental approach (using 
IC and 2D diode array measurements) takes an average about 2 hours in our clinic. 
Independent dose calculation followed by machine log file analysis can be a reliable 
tool to verify IMRT treatments. Additionally, independent dose calculations have 
the potential to identify several problems (heterogeneity calculations, data corrup-
tions, system failures) with the primary TPS, which generally are not identifiable 
with a measurement-based approach. Additionally, machine log file analysis can 
identify many problems (gantry, collimator, jaw setting) which also may not be 
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detected with a measurement-based approach. Machine log file analysis could also 
detect performance problems for individual MLC leaves which could be masked 
in the analysis of a measured fluence.  
PACS numbers: 87.53.Bn, 87.55.Qr, 87.55.km, 87.57.Uq
Key words: quality assurance, IMRT, dose calculations, machine log file. 
 
I. INTRODUCTION
Since the introduction of intensity-modulated radiotherapy (IMRT), the physical measurements 
and patient-specific QA procedures to validate each IMRT plan before treatment have been 
considered an integral component of this delivery technique.(1,2) The comprehensive QA is es-
sential for IMRT due to the complex nature of treatment planning and multitude of interfaces 
between the treatment planning system (TPS) and treatment delivery. Recommendations and 
guidelines for the appropriate implementation of IMRT and support of an adequate QA pro-
gram to safely delivery IMRT treatments were provided in recent publications and reports.(2-4) 
Currently, experimental methods are predominantly used for patient-specific IMRT delivery 
verifications. Typical measurement-based procedures for pretreatment dosimetric verification 
include point dose measurements using ion chambers (IC) for a delivery including all treatment 
fields at the planned gantry angle, and 2D dosimetry measurement using radiographic films or 
2D diode or ion chamber arrays at a vertical gantry angle for individual IMRT fields.(5-9) 
Traditional measurement-based QA verification techniques may not be sensitive enough to 
detect many types of failures (such as plan transfer errors, beam delivery error, dose calculations 
errors) in the IMRT process.(10,11) Traditional IMRT QA processes rely on dose verification 
measurements in water equivalent plastic phantoms, which do not represent patient geometry 
or tissue heterogeneities. This oversimplification may not be able to identify calculation errors 
in some treatment sites. Additionally, creation of QA plans in the primary TPS requires recal-
culation of dose on the water equivalent phantom or 2D measurement array. This recalculation 
breaks the connection between the patient treatment plan and the QA plan, and any potential 
errors which were present in the calculation of the patient treatment plan may not be propagated 
to the phantom QA plan due to resetting of the calculation. Furthermore, experimental methods 
are time-consuming and labor-intensive, and require access to the treatment machine. There is 
a growing interest in using independent dose calculation(12-15) and machine log files(16-18) for 
QA of IMRT delivery. Dietmar et al.(13) have proposed a semi-analytical fluence based dose 
calculation for patient-specific monitor unit (MU) verification. Monte-Carlo–based independent 
dose calculations have been suggested for routine IMRT verification(14) and even to replace the 
dosimetric verification in phantom.(15) In addition to research and clinical interest, the com-
mercial interest in independent dose calculation for IMRT is growing and tools have become 
commercially available.(19,20) Recently there is still a debate to evaluate the necessity and ef-
fectiveness of dosimetric validation of each individual IMRT treatment plan with dosimetric 
plan before delivery.(12) The machine log file analysis has been proposed as an alternative for 
IMRT QA by several groups.(16) Log files have been used to study step-and-shoot and dynamic 
MLC deliveries.(17,18) A commercial software that automatically verifies delivery accuracy 
for patient treatment using the machine log files has become available. In our department, 
log file analysis has been a routine component of patient-specific IMRT QA procedure for 
several years.(21)
It has been shown that no single QA technique can mitigate all the errors that can happen 
in the IMRT process.(22,23) Table 1 shows a qualitative analysis of relative effectiveness of 
different IMRT verification for catching errors that can happen in IMRT delivery. It is criti-
cal to evaluate the efficiency and effectiveness of traditional QA approaches, and explore the 
possibility of augmenting or replacing current QA techniques with more effective, systematic, 
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Table 1. A qualitative analysis of effectiveness of QA techniques to catch some potential discrepancy or error that 
could happen in an IMRT treatment. Note: only a few are mentioned here and only pretreatment QA techniques 
are analyzed. 
      Independent
   Field-by-Field  Composite  Dose 
 Data Transfer, Delivery Error, Point Dose Planar Dose Planar Dose DynaLog Calculation 
 Planning Error Type Measurementa QAb QAc QAd QAe
Beam Parameters Discrepancy  
During Data Transfer or  
Machine Delivery     
Gantry Angle 3 5 4 1 5
Collimator Jaw Setting 3 3 3 1 5
Collimator Angle 3 3 3 1 5
MLC  Positioning Error  4 3 3 1 5
MUs 1 1 3 5 5
Couch Angle Error  2 5 2 5 5
Machine Issues/Data  
Transfer Issues     
Dosimetry Characteristic –  
 Energy Change, Symmetry and  4 4 4 5 5 
 Flatness Off  
Absolute Dose Output Calibration 5 5 5 5 5
Relative Dose Output – Small  
 Field Output Off 
1 1 1 5 5
One Segment Dropped Out or  
 Not Transferred Properly 
4 3 4 1 5
One Field Not Transferred Correctly 4 2 3 1 5
Demanding MLC Sequence or  
 MLC Positioning Issues – Beam  4 4 4 1 5 
 Hold Off 
TPS Beam Modeling Issues     
Small Field Out Prediction Issue 2 2 2 5 1
Heterogeneity Correction Issues 5 5 5 5 1
Wrong CT to ED  5 5 5 5 2
DVH Calculation Discrepancy 5 5 5 5 1
In vivo Changes     
Beam Data Modification After  
 Pretreatment QA and Other Machine  5 5 5 5 5 
 Issues During Each Fraction 
IGRT Issues     
Anatomy Changes, localization  
 Issues, Setup Issues 
5 5 5 5 5
Treatment Planning     
Isocenter Placement, Prescription,  
 Wrong CT Voxel Size, Plan Quality 
5 5 5 5 5
Note: 1 is most effective, 4 is least effective, and 5 is not possible to find from QA test results. 
a Point dose measurement refers to ion chamber measurement with one or two points in a composite fashion (i.e., all 
beam delivered to a water equivalent phantom as it would be delivered to the patient).
b Field-by-field planar dose measurement: all beams delivered from AP direction with gantry and could reset to default 
position.
c Composite planar dose QA refers to measuring a plane using a 2D detector embedded in a phantom and the QA is 
performed with actual beam parameters as it will be delivered to the patients. 
d DynaLog QA: analysis of machine log file collected by delivering the actual plan to air or during composite point or 
planar dose measurement, as explained in a) and c).
e  Independent dose calculation is verifying the dose distribution of the planning system by recalculating in an inde-
pendent dose calculation by exporting DICOM RT files (Plan, Dose, Images, Structure set ) and any POIs. 
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reliable, and efficient methods. In this work, we have evaluated the efficiency and effectiveness 
of independent dose calculation in combination with machine log files analysis as an approach 
to IMRT QA. We accomplish this by: 
a) Comparing the efficiency and accuracy of dose calculation and machine log file analysis 
QA paradigm against current measurement based technique. 
b) Evaluating the potential of two paradigms for error detection effectiveness and reliability.
To do this, we chose to use another commercial treatment planning system to verify the 
IMRT dose distribution computed by the primary treatment planning system. Independent dose 
calculation does not verify the MLC performance during IMRT delivery, although it may reduce 
or reveal errors/inconsistencies in the treatment planning system and process. We propose to 
perform the machine log file analysis to supplement the calculation-based QA to validate data 
transfer and delivery performance of MLCs. 
 
II. MATERIALS AND METHODS
A.  Treatment plans 
In the present study, 16 IMRT plans have been evaluated by experimental methods and by an 
independent dose calculation method followed by machine log file analysis. Treatment plans with 
fixed beams and static multileaf collimator (SMLC) IMRT treatment plans were chosen for this 
study. Treatment sites and number of plans included in the study were: 5 head-and-neck plans, 
3 rectum plans, 3 breast plans all using 6 MV, and 5 prostate plans using 18 MV. The average 
number of beams used in this study for head-and-neck, rectum, breast, and prostate were 9, 9, 
10, and 7, respectively. Treatment plans were created using Pinnacle 9.0 TPS (Philips Medical 
Systems, Fitchburg, WI). The number of segments used per beam varied between 4–12, while 
the total number of segments varied between 40 and 78 per treatment plan. All plans were 
optimized using direct machine parameter optimization (DMPO).(24)
B.  Verification procedures
B.1 Traditional measurement-based IMRT QA 
Figure 1 shows the entire verification process presented in this paper (steps grouped inside 
the black box). After an IMRT treatment plan was approved for treatment, it was recalculated 
using the same beam orientations and MUs, but replacing the patient CT dataset with a water 
equivalent phantom (14 × 14 × 15 cm3). The phantom has inserts to accommodate two small-
volume ionization chambers (IC) anywhere within the box at a 0.5 cm resolution.(6) Two IC 
point measurements were performed for each approved plan. Additionally, planar dosimetry 
QA for each field of each plan was performed using a 2D diode array (MapCHECK, Sun 
Nuclear Corporation, Melbourne, FL) mounted using a custom-built water equivalent plastic 
phantom. The MapCHECK device consists of 445 N-type diodes that are in 22 by 22 cm2 2D 
array with variable spacing of 7 and 14 mm between diodes. Calculated planned fluences were 
copied onto the verification phantom in such a way that the high-dose region is located in the 
central area where there is high detector density of the MapCHECK device. The verification 
measurements were performed using a static gantry that is perpendicular to the measurement 
plane. The measured fluence maps of the individual beams were compared to the fluence maps 
computed by the TPS. The goal was that IC measurements should verify the absolute dosim-
etry, while the planar dosimetry measurements validate the relative dose distributions of the 
individual beams.
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B.2  Calculation-based verification method 
The proposed calculation-based verification method consists of independent dose calculation 
and machine log file analysis. The process for independent calculation-based QA is also shown 
in the flowchart of Fig. 1. All treatment plans were generated on the Pinnacle treatment plan-
ning system. DICOM RT files which include RT dose, RT plan, RT structures, and CT images 
were exported to another commissioned and clinically used commercial treatment planning 
system (Eclipse V 8.2.0, Varian Medical Systems, Palo Alto CA). The dose distributions were 
recalculated using Eclipses’ analytical anisotropic algorithm (AAA).(25) The point doses and 
DVHs were exported in DICOM format and analyzed in Eclipse TPS. The planar dose files 
from both treatment planning systems were exported into I’MRT MatriXX (IBA dosimetry, 
Bartlett, TN) for qualitative and quantitative gamma analysis. The use of independent dose 
calculation is an alternative method to evaluate the accuracy of the treatment planning system’s 
dose calculations, including heterogeneity corrections.  
The Pinnacle plan was calculated using Collapsed Cone Algorithm with dose grid size of 
3 mm × 3 mm × 3 mm while, for Eclipse treatment planning system, Anisotropic Analytical 
Algorithm was used with a dose grid size of 2.5 mm × 2.5 mm × 3 mm. Both the systems have 
implemented convolution superposition algorithms in their own way. The dose-volume histo-
grams (DVH) were computed using Eclipse TPS for both Pinnacle and Eclipse dose grids. The 
DVHs and the point doses of two plans were then evaluated for PTV and critical structures.
The machine log files were captured during pretreatment ion chamber QA measurements. 
Varian linear accelerators (linac) write the actual machine parameters every 50 ms, and store 
them in a file (DynaLog) on the linac control console and MLC workstation. We used log files 
from Varian Trilogy and iX machines which record machine parameters every 50 ms, while 
the Varian TrueBeam machine, which records machine parameters every 10–20 ms, was not 
Fig. 1. Process flow for independent dose calculations with machine log file analysis and measured-based QA in 
our clinic.
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considered for this study. The DynaLog files include beam on/off status, gantry angle, collima-
tor angle, jaw positions, and MLC leaf positions for all control points and delivered beam MU, 
etc. These log files are accessible after the delivery of each fraction of the treatment.  
After an IMRT treatment plan is approved, it is exported to the R&V system and delivered 
on the linac machine for point dose (IC) QA measurements, and the machine log files stored 
during the delivery were transferred to and stored in a folder on a network drive. In this study, 
we capture the DynaLog files that were recorded during pretreatment point dose measurement. 
In a parallel path, the treatment plan was exported as a DICOM file containing the planned 
values of the machine parameters to the same network drive folder. Semi-automatic machine 
log file analysis is performed using in-house–developed MATLAB (MathWorks Inc., Natick, 
MA) software which compares the patient identification information (name, ID number, etc.), 
log file integrity, and the delivered machine parameters for each beam with the respective 
planned values. Beam parameters include gantry angle, collimator angle, number of segments, 
and MLC leaf positions for all control points. In addition, based on the beam on/off status and 
MLC leaf positions retrieved from the machine log files, the software computes the equivalent 
fluence map (in MUs) at the isocenter for each delivered beam, compares it against the planned 
beam fluence map reconstructed using the same algorithm, and calculates pixel-by-pixel fluence 
difference between the two maps. Finally, the software generates a summary report of all the 
beam parameters, and three fluence maps for each beam. The report is color-coded and includes 
warning messages for parameters that are outside specified tolerances.  
 
III. RESULTS 
A.  Evaluation of measurement based IC and planar dosimetry IMRT QA
In the past three years, we have performed ~ 4000 IMRT QAs with ion chambers, field-by-field 
planar dosimetry and composite planar dosimetry. We have not found any errors that would 
result in replanning of the patient treatment or modification of treatment delivery parameters. 
We have treated variety of different sites with SMLC and DMLC technique. However, we have 
repeated ~ 15% of the QA measurements because of incorrectly generated/delivered QA plan, 
equipment failures, selected points being in high dose gradient regions, or wrong documenta-
tion of QA plan (shifts or point coordinates), resulting in additional time and resources. While 
this is true, it doesn’t mean that there were no discrepancies between planned and delivered 
treatments. We have found instances where there were discrepancies in the R&V system that 
were caused by data entry or other human errors, and for which the pretreatment QA methods 
were insensitive and therefore did not catch, but that were discovered during initial and weekly 
chart checks.  
B.  Validation of independent dose calculation and machine log QA paradigm with 
measurements
The IMRT phantom plans were verified with ICs and MapCHECK. For composite IMRT plan 
deliveries, average deviation between IC measurements and point dose calculation with Pin-
nacle and Eclipse for head-and-neck plans for all the selected patients were 1.2 ± 1.3% and 
1.4 ± 1.6%, respectively (Table 2). MapCHECK measurement and dose distribution computed 
from Pinnacle were compared using the gamma evaluation method with 3% dose difference 
and 3 mm distance-to-agreement as acceptance criteria. Dose distributions obtained from Pin-
nacle were used as reference. Table 2 also lists the average gamma passing rate for the various 
treatment sites.
Figure 2 represents typical line dose profiles of the calculations and measurements for a 
single head-and-neck (H&N) treatment field. The insert shows the dose distribution and the 
position of the line profile. Both the calculated dose distribution using Eclipse and measured 
using MapCHECK match quite well with the calculated from Pinnacle. Figure 3 shows the 
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 histograms of the deviations of the MapCHECK measurements and Eclipse calculations com-
pared to Pinnacle calculated IMRT plan on a pixel-by-pixel basis for the H&N patient presented 
in Fig. 2. The results demonstrate a little broadening of measurement data and not in the eclipse 
Table 2. Ion chamber measures to validate independent dose calculation technique.
 Eclipse Calculated Dose /  Measured / Pinnacle MapCHECK Gamma
 Pinnacle Calculated Dose Calculated Dose Passing Rate
 (Avg ± STD) (Avg ± STD)  (Avg ± STD) %
 Treatment Site IC1 IC2 IC1 IC2
 Head-and- Neck 0.972±0.005 0.980±0.009 1.022±0.008 1.013±0.010 96.3±1.62
 Breast 0.990±0.004 0.996±0.01 1.010±0.006 1.009±0.020 94.8±1.13
 Prostate 0.995±0.01 1.01±0.004 0.994±0.009 0.997±0.012 98.2±0.58
 Rectum 0.975±0.008 1.005±0.01 1.017±0.016 1.017±0.025 94.9±1.68
Fig. 2. Line dose profiles for an H&N IMRT plan verified by MapCHECK for Pinnacle and Eclipse calculations.
Fig. 3. Dose difference derived from the difference between measurements vs. Pinnacle and Eclipse calculations vs. 
Pinnacle.
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calculations. The broadening of the MapCHECK measurements may be from the small errors 
in positioning the phantom and the resolution of the diode array. 
The dose calculations using two different treatment planning systems were also compared 
based on the treatment site. Figure 4 shows the dose map of a representative head-and-neck 
case obtained with Pinnacle and Eclipse. Figure 4(c) and (d) shows the difference in dose and 
in gamma function analysis. The 2D gamma evaluation quantity was calculated using 3% 
dose and 3 mm spatial acceptance criteria. Table 3 shows the DVH indices for head-and-neck 
and rectum corresponding to Pinnacle and Eclipse. The mean dose differences are within 2% 
for both cases. In the same way, Table 4 lists the DVH indices for breast and prostate cases. 
The independent dose calculation deviates from Pinnacle by less than 1.8% for both PTV and 
critical structures.
It has been pointed out that independent dose calculations based on the exported DICOM 
file from Pinnacle to Eclipse do not check the potential error in the actual MLC performance of 
the treatment unit and accuracy of the delivery. The machine log files analysis for two beams 
delivered for a head-and-neck patient, shown in Fig. 5, reveals the fluence maps of planned and 
delivered (without considering the scattering) and their difference. This report also includes 
the status of several beam parameters including gantry angle, collimator angle, jaw positions, 
delivered MU, and MLC errors. If the actual parameters are within the set tolerance, the check 
results are displayed in green, otherwise as a “warning” in yellow. The tolerances for gantry 
angle, collimator, jaw position, and MLC leaf positions are 0.1°, 0.1°, 1 mm and 2 mm, respec-
tively. We have found that the maximal MLC errors for the 16 patients were less than 0.5 mm. 
The passing rate at 2% (3%) means the percentage of the number of pixels with error less than 
the 2% (3%) of the maximal fluence (in MU) of the entire beam. 
Fig. 4. Dose map of a representative H&N case obtained with Pinnacle and Eclipse: (a) from Pinnacle; (b) from Eclipse; 
(c) difference; (d) 2D gamma.
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Table 3. DVH indices for head-and-neck and rectum cases.
 Head-and-Neck Rectum
 PTV & Critical   Pinnacle Eclipse Pinnacle Eclipse
 Structures Dose Indices (Avg.±SD) (Avg.±SD) (Avg.±SD) (Avg.±SD)
  V 95%  98.7±1.3 96.9±1.7 96.9±5.4 95.8±7.3
  V 105%  34.3±33.2 23.4±25.3 16.7±25.3 16.1±26.5
  V 107%  14.3±17.7 8.2±10.0 5.3±9.0 5.7±9.8
 PTV1 Min. dose % 96.9±2.0 95.0±1.9 96.3±4.9 95.9±5.1
  D5%-95% 8.9±2.8 10.0±2.9 7.4±3.2 7.5±3.1
  D3%-93% 8.4±2.5 9.8±2.7 7.2±3.1 7.4±3.0
  Mean dose (cGy) 7236.3±140.3 7143.0±172.3 4281.1±1543.0 4270.7±1550.6
  V 95%  99.6±0.0 99.1±0.3 98.8±1.2 98.5±1.5
  V 105%  69.3±11.6 58.1±7.3 72.8±9.4 71.0±11.2
  V 107%  51.9±12.6 41.2±6.7 62.1±8.5 60.3±10.1
 PTV2 Min. dose  97.0±0.2 95.3±0.7 95.8±4.2 95.3±4.8
  D5%-95% 20.4±5.0 20.7±4.8 21.7±9.0 21.6±8.7
  D3%-93% 22.0±5.4 22.4±4.9 21.4±9.1 21.3±8.7
  Mean dose (cGy) 5937.7±109.60 5862.2±128.3 4035.1±1566.2 4025.2±1570.7
 
Lt. Parotids
 V26Gy   62.0±32.1 59.9±30.7 -- -- 
  Mean dose (cGy) 3586.6±1801.1 3494.6±1736.3 -- --
 
Rt. Parotids
 V26Gy  53.7±40.4 52.3±40.7 -- -- 
  Mean dose (cGy) 3122.4±2020.3 3068.4±2016.6 -- --
 Spinal Cord Max. dose  3762.1±260.6 3599.2±257.2 -- --
 
Small Bowel
 V40Gy -- -- 582.0±988.4 595.7±1012.2
  Mean dose (cGy) -- -- 1780.2±1102.2 1772.2±1097.8
Table 4. DVH indices for breast and prostate cases.
 Breast Prostate
 PTV & Critical Dose Pinnacle Eclipse Pinnacle Eclipse
 Structures Indicies (Avg.±SD) (Avg.±SD) (Avg.±SD) (Avg.±SD)
  V 95%  89.9±12.5 77.9±23.5 100.0±0.1 100.0±0.0
  V 105%  3.6±5.1 1.5±2.1 32.1±31.4 47.7±37.9
  V 107%  0.6±0.8 0.2±0.2 1.9±2.6 12.4±17.0
 PTV Min. dose  95.4±0.9 94.0±1.4 100.7±0.6 100.8±1.3
  D5%-95% 8.1±0.1 8.8±0.3 3.1±1.4 3.6±1.7
  D3%-93% 8.1±0.1 8.7±0.2 3.1±1.3 3.5±1.6
  Mean dose  4988.5±148.4 4923.2±147.6 6779.6±34.8 6828.6±50.1
 Ipsilateral Lung
 V20 26.3±3.8 26.0±3.9 -- --
  Mean dose (cGy)  1363.4±63.1 1375.4±66.5 -- --
 
Heart
 V20 6.7±9.5 6.8±9.7 -- --
  Mean dose (cGy) 982.7±506.2 965.0±524.0 -- --
 Spinal Cord Max. dose (cGy) 1241.7±354.1 1267.3±323.1 -- --
  V65 -- -- 10.3±1.4 10.5±1.3
 Rectum V40 -- -- 27.1±1.8 27.3±2.0
  Mean dose (cGy) -- -- 2721.6±171.6 2743.2±152.0
  V65 -- -- 15.6±5.6 16.0±5.6
 Bladder V40 -- -- 25.9±6.8 26.6±6.9
  Mean dose (cGy) -- -- 2408.5±534.0 2461.7±529.9
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Fig. 5. Machine log analysis. Gantry, jaw, and collimator angle, MLC positions, MU, and fluence map are compared.
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C.   Efficiency of independent dose calculation and machine log file analysis 
paradigm
Table 5 shows the comparison of the total time for experimental IMRT verification in solid 
phantom, based on IC and MapCHECK measurements, and calculation-based approach. The 
independent dose calculation with the machine log analysis can be done during the day and 
only takes 32 minutes. This time comparison favors the independent dose calculation, as the 
experimental approach takes about 2 hours.
Table 5. Process flow timeline.
   Experimental-based  Computation-based
 Steps Time Scale Approach Method
 1 Making a verification plan for measurements
  (IC and 2D verification plans)  
35 min 15(capturing DynaLog)
 2 Exporting verification plan for delivery  3 min -
 3 1D and 2D verification at LINAC  60 min -
 4 Data analysis of the measurement data  15 min -
 5 Export the plan from Pinnacle to Eclipse  - 10 min
 6 Independent dose calculation in Eclipse  -  8 min
 7 DVH comparison and analysis - 6 min
 8 Machine log analysis - 3 min
 9 Documentation  5 min 5 min
 Total Time    118 min 47 min
 
IV. DISCUSSION
There are many potential errors that can arise during the IMRT planning and delivery, such as 
dose calculation inaccuracies, plan transfer errors, beam delivery errors, patient setup errors, 
and target location uncertainties due to organ motion. A comprehensive quality assurance pro-
gram should be established to efficiently check these potential errors and to ensure that dose 
distribution planned on an IMRT treatment planning system will be delivered accurately and 
safely. Current patient-specific QA techniques are performed by irradiating a water equivalent 
phantom that contains film, IC arrays or equivalent dose measurement tools to verify that the 
dose delivered is the dose planned. These methods can detect large errors in beam delivery, but 
might not detect dose calculation errors. Furthermore, the verification measurements are based 
on the homogenous phantom, which does not take into account the heterogeneities in patient’s 
anatomy. The measurement-based QA methodology in water equivalent phantoms may not 
catch the errors associated with lack of electronic equilibrium caused by small segments in the 
presence of heterogeneities. The independent dose calculation can catch the serious errors in 
heterogeneity calculation or beam modeling. 
It has been recognized that today’s patient-specific measurement-based QA has serious 
limitations and it is also time-consuming and labor-intensive. The value of validating individual 
plans has been questioned, and there has been a debate whether validating treatment plan is 
worthwhile after the commission process has been completed.(12,26,27,28) With IMRT, proper 
commissioning will help avoid most systematic errors. Independent dose calculation can serve as 
an alternative verification method which can free up time for the physicist to evaluate the entire 
scope of an IMRT treatment. The other advantage of independent dose calculation method is that 
the linear accelerator time is not required. And the independent dose calculation and machine 
log file analysis can be done, on average, in 32 minutes, which is much more efficient than the 
measured-based QA approach. The efficiency of the independent dose computation and log file 
analysis method can be improved by designing a fully automatic QA tool. A comprehensive 
commercial solution that would automate the whole process will make it even more efficient. 
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In this study, we have used the 2D gamma to evaluate the dose distribution accuracy between 
planning systems, but a full 3D gamma evaluation would be useful. 3D gamma can also aid 
us finding discrepancy in areas that are not contoured as structures where discrepancy cannot 
be figured out from DVH metrics. This 3D gamma tool would add additional robustness to the 
independent dose calculation-based QA paradigm.   
We used a commercial treatment planning system as an independent dose calculator instead 
of Monte Carlo method because Eclipse is a FDA-approved commercial treatment planning 
system and the dose calculations on this system are reasonably fast. The use of Monte Carlo 
has been proposed by several authors,(29-30) but we avoided that for two reasons: i) we believe 
the goal of the independent dose calculator is to act as a QA tool looking for major errors in-
stead of determining the accuracy of the commissioned treatment planning system algorithm 
and beam model; ii) from an efficiency aspect, the time required to compute independent dose 
calculations with Monte Carlo are prohibitively long. 
It has been realized that the independent dose calculation alone is not sufficient for a com-
prehensive QA program because the data transfer from the TPS to the linear accelerators and 
the performance of the delivery unit are not checked. Therefore, a periodic QA testing of the 
machine delivery accuracy is required. Computer-based machine log file analysis should catch 
any errors associated with plan transfers and the delivery problems. The machine log file analysis 
should authenticate the delivery quality. Also the machine log file QA is a number-to-number 
comparison of data transferred from treatment planning system to data delivered by the linear 
accelerator and is more sensitive to detecting discrepancies of the order or 1 mm and 1 degree 
compared to measurement-based method. The sensitivity of IC and planar dose measurements 
is determined by volume of ion chambers and resolution of MapCHECK or MatriXX. In our 
clinics, the machine log file QA have detected data transfer errors, jaw position errors, and MLC 
errors which were not caught in IC and planar dose measurements.(21) Most of these  errors 
were related to the data transfer and human error, and the sensitivity and efficiency of the IC 
and planar dose measurements in mitigating errors were revealed.(21) This work also leads us 
to believe that current QA methodology has short comings. 
The workflow for Pinnacle patients using verification by independent dose calculation method 
is to export the clinically approved treatment plans to Eclipse planning system to perform in-
dependent dose calculations using the AAA algorithm. If the Eclipse dose-volume indices for 
PTVs and OARs match the Pinnacle TPS within 3%, the patient should go for treatment without 
QA measurements, and one can perform machine log file analysis on the patient’s first treatment 
fraction to validate the delivered treatment beam parameters against the planned. The benefit 
of doing machine log file analysis on first fraction is that there is no delay in process because 
of QA, and the treatment can resume immediately after the plan is ready. Also, any changes to 
the treatment record after pretreatment checks are made could be detected. The downside of 
this approach is that, if there are any errors in the beam parameters prepared for delivery, the 
error would be found only after delivering a dosimetrically different dose than the plan for the 
first fraction. Therefore, this methodology may not be suitable for single fraction treatments 
as well as hypofractionated ESRT treatments. For this case, a QA beam could be delivered and 
the machine log file analysis could be done before the patient treatment. Even if a pretreat-
ment IC QA is performed, it would be a better practice to perform machine log QA analysis 
after first fraction to ensure nothing has changed after QA and initial approval. One could also 
evaluate a paradigm doing DynaLog QA, which is performed after every field to reduce the 
risk. Also DynaLog QA can be performed on pretreatment and also on the first fraction as an 
in vivo measurement. In our clinic, we are performing DynaLog QA for every field, for every 
fraction, and for every IMRT patient, to study the effectiveness of that paradigm,(31) which will 
be reported in a separate manuscript. The method of choice should be based on effectiveness, 
efficiency, and safety of the delivery to the patients.         
The paradigm shift from measurement-based patient-specific QA verification to a computa-
tion-based methodology may have significant gain on the QA timeline and workflow, particularly 
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towards implementation of adaptive radiation therapy. However, the transition should be gradual 
so as to provide enough confidence in IMRT verifications. At the start of clinical implementation 
of any new IMRT technique, it is strongly recommended to perform measurements of the 3D dose 
distribution delivered to a phantom and to compare with planned dose distributions. It should 
be kept in mind that the computation-based methods do not exclude the measurement-based 
methods for some cases. When the independent dose calculations and machine log files analysis 
yield an unacceptable result or when the independent dose calculations do not give satisfactory 
results, the experimental-based measurement or other investigation should be systematically 
performed to track the errors. Also, at the time of upgrade or when any major component of 
treatment planning program is upgraded, it is advised to perform measurement-based QA. Since 
measurement-based methods are typically performed on homogeneous phantom, an independent 
dose calculation with heterogeneity correction should also be performed.
To implement the calculation-based method as a QA approach using Eclipse, the indepen-
dent dose calculation software has to be modeled accurately because the results of independent 
IMRT dose calculation are dependent on the leaf transmission, rounded leaf ends, and the 
tongue-and-groove effect. It should be noted that dose calculation discrepancy does exist due 
to differences between the TPSs treatment of heterogeneities (collapsed cone vs. AAA). The 
verification by independent dose calculation shows the difference in dose calculations between 
the Pinnacle and Eclipse treatment planning systems is within ± 3% for head-and-neck, prostate, 
breast, and rectum cases. For sites in which tissues are nearly homogeneous (prostate), little 
heterogeneity error would be expected from independent of the dose calculation algorithm. For 
heterogeneous geometries (lung, head-and-neck), the heterogeneity errors would be expected 
to be greater. These were also seen in Tables 3 and 4 from our study. Approximations or inac-
curacies in the conversion from MLC leaf sequences to fluence or intensity maps to be used 
by the dose calculation algorithm in Eclipse and Pinnacle treatment systems could also lead 
the dose differences between the two treatment planning systems. Such discrepancies should 
be expected and understood, while variance from such discrepancy should be an indicator of 
errors. Depending on the limitation and implementation of the algorithms that are used, there 
could be large discrepancies in certain situations (e.g., lung tumors with small PTVs) with AAA 
and collapsed cone algorithms.(32) Thus this technique has limitations, and in such scenarios 
one must apply it with an understanding of the differences in algorithms.
The goal of the study is not to propose the use or purchase of the second commercial 
planning system. The goal is to study different QA paradigms in a quest to understand the ef-
fectiveness and efficiency. We had several choices for independent dose calculation software. 
We consciously decided to use a commercial, extensively tested independent dose calculation 
system as the secondary TPS. The reason for this was to choose an equally robust and verified 
dose calculator to avoid introducing other uncertainties into the paradigm. We thought the best 
choice would be a commissioned FDA-approved TPS which has been routinely used in our 
clinic for a several years.
This is a process that is shown to be effective and it is important to have independent dose 




The present verification procedure with independent dose calculation followed by machine log 
file analysis is a reliable tool to verify the IMRT treatment. It allows the assessment of dose 
distribution in the patient anatomy, which cannot be obtained with conventional measurements 
using ICs or MapCHECK in a homogenous phantom. It can verify not only the calculation 
inaccuracies, but also verify the data transfer and evaluate the performance of the MLC deliv-
ery. Machine log file analysis is a much more sensitive tool of data transfer/entry discrepancy 
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than measurement-based techniques. This method offers significant advantage in reducing the 
time needed for the QA and it is less labor-intensive. With the IMRT QA program becoming 
more mature, independent dose calculations and machine log analysis may be used to replace 
or compliment experimental-based verification methods.
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